Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WJ-MSC for Ischemia-Reperfusion Injury in STEMI
NCT03533153Phase 2Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Mar 2021
- Primary completion
- Dec 2023
- Modality
- Stem Cell Therapies
01
Overview
A Phase 2 trial of wharton's jelly mesenchymal stromal cells in ST-segment elevation myocardial infarction (STEMI), sponsored by Nanjing Drum-Tower Hospital. Planned start Mar 2021; status: not yet recruiting.
02
Drugs
wharton's jelly mesenchymal stromal cells
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT03533153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03533153.